Pharmacokinetics, safety, efficacy and immunogenicity of Adalimumab biosimilar ABP-501in rheumatoid arthritis and plaque psoriasis
This thesis is submitted in partial fulfillment of the requirements for the degree of Bachelor of Pharmacy, 2021.
Huvudupphovsman: | Akter, Anika |
---|---|
Övriga upphovsmän: | Alam, Marzia |
Materialtyp: | Lärdomsprov |
Språk: | English |
Publicerad: |
Brac University
2022
|
Ämnen: | |
Länkar: | http://hdl.handle.net/10361/17039 |
Liknande verk
-
Biologics and Biosimilars as Treatment Options for Psoriasis
av: Moya, Amena Khatun
Publicerad: (2023) -
Importance of biologics in rheumatoid arthritis management
av: Riyadh, S. M.
Publicerad: (2022) -
TNF-α inhibitor-induced alopecia in psoriatic disease patients: a pharmacovigilance study
av: Afroza, Halima
Publicerad: (2024) -
Importance of biologically active agents over other therapies in Rheumatoid Arthritis- a review
av: Mehreen, Elnaj
Publicerad: (2021) -
A pharmacovigilance study on FDA approved interleukin inhibitor-associated alopecia in the treatment of psoriasis
av: Islam, Nahidul
Publicerad: (2023)